Coherus Oncology, Inc. (CHRS) Financials

CHRS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 266.0 million 187.4 million
Dec. 31, 2025 258.3 million 197.3 million
Sept. 30, 2025 516.5 million 428.7 million
June 30, 2025 439.5 million 319.6 million

CHRS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -57.9 million ?
Dec. 31, 2025 -19.7 million 10.8 million
Sept. 30, 2025 -46.3 million 3.4 million
June 30, 2025 -46.6 million 5.4 million

CHRS Net Income

No data available :(

CHRS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 167.0 million 51.5 million 954000
Dec. 31, 2025 172.1 million 37.1 million 3.3 million
Sept. 30, 2025 191.7 million 37.0 million 3.7 million
June 30, 2025 237.6 million 36.9 million 4.2 million

CHRS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 136.4 million
Dec. 31, 2025 120.4 million
Sept. 30, 2025 116.2 million
June 30, 2025 116.1 million

CHRS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 20.7 million 23.1 million -
Dec. 31, 2025 - 30.1 million 23.6 million -
Sept. 30, 2025 - 26.3 million 22.8 million -
June 30, 2025 - 25.3 million 26.0 million -

CHRS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 12.3 million 4.7 million
Dec. 31, 2025 12.7 million 4.9 million
Sept. 30, 2025 11.6 million 4.7 million
June 30, 2025 10.3 million 4.4 million

CHRS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

CHRS

Price: $1.41

52 week price:
0.73
2.62

Earnings Per Share: -1.42 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 749400

Ebitda: -55.8 million

Market Capitalization: 177.5 million

Links: